Summit Therapeutics plc (NASDAQ:SMMT) Q2 2019 Earnings Conference Call - Final Transcript
Oct 11, 2019 • 08:00 am ET
arguments to treat patients front line with ridinilazole at a fair price for its value. And we estimate that a drug that can reduce recurrences by an absolute 15%, remember 15, one five, which save [Phonetic] between $1.4 billion and $2.7 billion in the US alone and to put that in perspective in the phase 2 clinical trial, ridinilazole reduce recurrences by a larger amount by an absolute 20%. Thus Ri-CoDIFy is undertaking a deep analysis of the impact ridinilazole has on the microbiome patients compared to vancomycin and the ability of ridinilazole to treat CDI will simultaneously preventing damage to the microbiome is central to its ability to reduce rates of disease recurrence.
Interestingly, at the recent IDWeek conference, we were excited to present additional clinical data from the phase 2 trial and we showed new microbiome analysis that again highlighted the minimal impact of ridinilazole on the gut environment in stark comparison to the deleterious effects of vancomycin. We also showed effects on the metabolome and how ridinilazole treated metabolome is a better metabolome than one treated with vancomycin and also better able to resist C. difficile.
Further, we showed that ridinilazole significantly improved patient quality of life in early and long-term measures of physical and mental health. And to me, it was stunning that patients on ridinilazole scored better for quality of life after only five days of treatment. Our strategy of designing better products and demonstrating their clinical and economic benefits applies to all the candidates in our pipeline. In March, we unveiled our DDS-04 series for the treatment of Enterobacteriaceae infections and this series is part of a new class of antibiotics selective for Enterobacteriaceae such as E coli and Klebsiella pneumoniae.
We demonstrated further proof of concept data this past quarter in animal models of pneumonia and sepsis adding to the urinary tract infection data from ECCMID. With antibiotic resistance to Enterobacteriaceae rising, it's important to have new classes of antibiotics available which have the potential to be equipotent across resistant and non-resistant strains, and we currently in lead optimization. Also this quarter, we presented data on our new class of antibiotics for the treatment of gonorrhoeae SMT-571, its shown in vitro potency against multi and extensively drug resistants strains. Gonorrhoea is rapidly accruing resistance to standard of care. A combination of ceftriaxone and azithromycin and once it reaches 5% resistance, the WHO usually switches its guidelines to recommend the next available treatment, and as of now, there is no next treatment.
These are exciting products. But just to get back to the main issue here, our overwhelming focus is on ridinilazole that's where we are really putting all our efforts right now. Looking ahead, we're aiming to build a fully integrated business of new antibiotics and to market ridinilazole in the US. We expect top line results from the phase 3 trials in the second half of 2021. The trial initiation phase is progressing well with 17 countries open for enrollment, including nine